Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Vulvitis" patented technology

Vulvitis is inflammation of the vulva, the external female mammalian genitalia that include the labia majora, labia minora, clitoris, and introitus (the entrance to the vagina). It may co-occur as vulvovaginitis with vaginitis, inflammation of the vagina, and may have infectious or non-infectious causes. The warm and moist conditions of the vulva make it easily affected. Vulvitis is prone to occur in any female especially those who have certain sensitivities, infections, allergies, or diseases that make them likely to have vulvitis. Postmenopausal women and prepubescent girls are more prone to be affected by it, as compared to women in their menstruation period. It is so because they have low estrogen levels which makes their vulvar tissue thin and dry. Women having diabetes are also prone to be affected by vulvitis due to the high sugar content in their cells, increasing their vulnerability. Vulvitis is not a disease, it is just an inflammation caused by an infection, allergy or injury. Vulvitis may also be symptom of any sexually transmitted disease or a fungal infection.

Female antibacterial gel and preparation method thereof

The invention provides bacteriostatic gel for women and a preparation method thereof, and belongs to the technical field of gynecological gel. The gel comprises 97%-99% of a multi-layer structure base material and 1%-3% of a natural plant effective component. The effective components comprise seven natural components such as a fructus cnidii extract, a helichthys italica extract and a radix sophorae flavescentis extract, and the base material comprises multiple layers of hydrogel. In the use process of the bacteriostatic gel for women, the fructus cnidii extract and the radix sophorae flavescentis extract can directly kill pathogenic bacteria of bacterial vaginitis and have an inhibition effect on HPV viruses, and the tea leaf extract and the psidium guajava leaf extract have antioxidant and bacteriostatic characteristics, so that the capacity of removing harmful microorganisms can be further enhanced. And the base material comprising multiple layers of hydrogel not only can enable bacteriostatic and anti-inflammatory components to continuously act on a focus part and improve the treatment effect on vaginitis and vulvitis, but also can reduce direct stimulation of subsequent effective components on sensitive mucous membranes, and is especially suitable for mucous membrane fragile scenes such as gynecologic operations and acute inflammation stages.
Owner:GUANGXI ZHONGSHENG PHARMACEUTICAL CO LTD

Composition for the improvement, prevention, or treatment of vaginitis or vulvitis, containing Lactobacillus salivarius HHuMin-U

This invention provides a composition containing Lactobacillus salivarius HHuMin-U (KCCM13001P) for use in improving, preventing, or treating vaginitis or vulvitis. [Solution] A pharmaceutical composition for the prevention or treatment of vaginitis or vulvitis is provided, containing Lactobacillus salivarius HHuMin-U (KCCM13001P) as an active ingredient.
Owner:BIFIDO

Composition for improving, preventing or treating vaginitis or vulvitis comprising lactobacillus salivarius HHuMin-U

PendingCN122005622AEffective improvementeffective therapeuticAntipyreticAnalgesicsAntibiosisLactobacillus salivarius
The present invention relates to a composition for ameliorating, preventing or treating vaginitis or vulvitis, comprising Lactobacillus salivarius HHuMin-U, the composition of the present invention exhibiting an excellent antibacterial power against pathogenic bacteria inducing vaginitis and vulvitis, and being very effective in ameliorating and treating vaginitis and vulvitis.
Owner:BEAFED GMBH